Breaking News

Altamira Spins-Off Part of its Bentrio Business

Initiates strategic repositioning to focus on company’s core RNA delivery technology.

Altamira Therapeutics Ltd., a company developing therapeutics that address important unmet medical needs, entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG to a Swiss private equity investor as part of its strategic repositioning around its RNA delivery technology. The transaction is set to close on November 21, 2023. Medica’s key asset is Bentrio, a drug-free OTC nasal spray utilized for the treatment of allergic rhinitis, which has been cleare...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters